Literature DB >> 11027657

Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice.

I Todoroki1, T Joh, K Watanabe, M Miyashita, K Seno, T Nomura, H Ohara, Y Yokoyama, K Tochikubo, M Itoh.   

Abstract

We investigated the effect of DNA vaccines encoding H. pylori-heat shock protein A and B (pcDNA3.1-hspA and -hspB) on inducing immune responses against H. pylori in mice. C57BL/six mice aged 5 weeks were immunized by single injection of 10 microg of pcDNA3.1-hspA and pcDNA3.1-hspB into intracutaneous tissue. Plasmid DNA lacking the inserted hsp were injected as a control. Three months after vaccination, significant specific antibodies against H. pylori were detected by ELISA in the sera of vaccinated mice. Antibody isotypes were predominantly IgG2a (Th1-like) with pcDNA3.1-hspA and mixed IgG1/IgG2a (Th0-like) with pcDNA3.1-hspB. DNA vaccination dramatically suppressed colonies of bacteria in stomach of vaccinated mice (28,400 +/- 21,600/mm(2) for pcDNA3.1-hspA and 6800 +/- 3470/mm(2) for pcDNA3.1-hspB) compared to control mice (128,000 +/- 42,200/mm(2)). Histological analysis of the gastric mucosa demonstrated that the degree of gastritis was significantly lower in the vaccinated mice than in control mice. These results demonstrated that DNA vaccines encoding H. pylori-Hsp induce significant immune response against H. pylori to decrease gastric mucosal inflammation, indicating that a DNA vaccine can be a new approach against H. pylori in humans. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027657     DOI: 10.1006/bbrc.2000.3632

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  DNA vaccines for targeting bacterial infections.

Authors:  Mariana Ingolotti; Omkar Kawalekar; Devon J Shedlock; Karuppiah Muthumani; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2010-07       Impact factor: 5.217

2.  Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model.

Authors:  Michael Kotiw; Megan Johnson; Manisha Pandey; Scott Fry; Stuart L Hazell; Hans J Netter; Michael F Good; Colleen Olive
Journal:  Clin Vaccine Immunol       Date:  2011-12-28

3.  Diagnosis of Helicobacter pylori infection and diseases associated with Helicobacter pylori by Helicobacter pylori outer membrane proteins.

Authors:  Zheng Jiang; Ai-Long Huang; Xiao-Hong Tao; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

4.  Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity.

Authors:  Bo Sun; Zhao-Shen Li; Zhen-Xing Tu; Guo-Ming Xu; Yi-Qi Du
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

5.  Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.

Authors:  Zheng Jiang; Ai-Long Huang; Xiao-Hong Tao; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  Age-specific immune response to HspA in Helicobacter pylori-positive persons in Mexico.

Authors:  Peter P Eamranond; Javier Torres; Onofre Muñoz; Guillermo I Pérez-Pérez
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

7.  DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.

Authors:  Kimberly Campbell; Hong Diao; Jiaxiang Ji; Lynn Soong
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

8.  Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice.

Authors:  Christine A Garhart; Raymond W Redline; John G Nedrud; Steven J Czinn
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

9.  Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection.

Authors:  K L Kotloff; M B Sztein; S S Wasserman; G A Losonsky; S C DiLorenzo; R I Walker
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.